🔗 Share this article

As America proceeds with historic changes to its vaccination schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 shots throughout the global health crisis and has focused upon potential deaths after Covid vaccination in her recent time at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Schedule

Health officials were set to announce sweeping changes to the childhood immunization program in December, bringing the US with the Danish national calendar, according to reports – a substantial departure that would put the US out of alignment with a large portion of the international standard with little proof for benefit. The planned update has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the office this year.

A New Direction at the FDA

This interim role could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for halting certain childhood shot schedules in the US so as to align more similar to Denmark, a country with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Høeg has little discernible experience in medication creation, regulation or leadership, which has been typical for past directors of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Previous commissioners of the center would “understand regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who headed CBER have had.”

This division has an vast portfolio at the FDA, she emphasized.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and every single one need to be managed,” Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership component to the job, which oversees over 5,000 staff members. “It is a enormous leadership role, if you do it right,” she concluded.

Response and Disputed Policies

Regarding inquiries about Høeg’s credentials and whether this assignment indicates more teamwork among FDA leaders on immunizations, a press secretary responded that the “inquiries are based on inaccurate presumptions”.

“Her resume aligns with the responsibilities of her position,” the representative explained, pointing to the period Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's new expedited review system, a disputed rapid medication authorization process that reportedly concerned her predecessors. “How are these drugs being chosen for this expedited pathway? Who makes the decisions?” Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards less stringent rules of most medications, with the exception of shots.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, track record, Howard have noted. She released a analysis using non-validated public submissions to assess the rate of myocarditis after Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed altering rules for novel immunizations and discontinuing “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Høeg has according to sources floated the idea of excluding young men from getting COVID-19 vaccinations.

“She is an complete true believer who begins with her beliefs and reverse-engineers to accommodate the science in a very misleading, dishonest way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|